title: Guanidino compounds in guanidinoacetate methyltransferase deficiency, a new inborn error of creatine synthesis.
abstract: The first inborn error of creatine metabolism (guanidinoacetate methyltransferase [GAMT] deficiency) has recently been recognized in an infant with progressive extrapyramidal movement disorder. The diagnosis was established by creatine deficiency in the brain as detected by in vivo magnetic resonance spectroscopy and by defective GAMT activity and two mutant GAMT alleles in a liver biopsy. Here, we describe characteristic guanidino-compound patterns in body fluids of this index patient with GAMT deficiency. Concentrations of guanidino compounds (creatine and guanidinoacetate) and creatinine were determined by cation-exchange chromatography and by color reaction with picric acid, respectively, in urine, plasma, and cerebrospinal fluid (CSF). Creatine concentrations were low in plasma, CSF, and urine while guanidinoacetate concentrations were markedly elevated. Daily urinary creatinine excretion was low, whereas creatinine concentrations in random urine samples were not always discriminative. Guanidino compound to creatinine ratios were not informative, as low creatinine concentrations resulted in high values for all determined compounds. During a 22-month period of oral treatment with creatine-monohydrate, plasma and urinary creatine concentrations increased to levels high above the normal range, and daily urinary creatinine excretion-proportional to total body creatine-became normalized. Guanidinoacetate concentrations remained elevated even during additional substitution of ornithine, which inhibits guanidinoacetate synthesis in vitro. The results indicate that GAMT deficiency can be recognized noninvasively by determination of guanidino compounds (creatine and guanidinoacetate) in body fluids. A deficiency of creatine, but not an accumulation of guanidinoacetate, can be corrected by treatment with oral creatine substitution.
authors.affiliation: Department of Pediatric Neurology, University Children's Hospital, Göttingen, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Stöckler
authors.forename: B
authors.initials: B
authors.lastname: Marescau
authors.forename: P P
authors.initials: PP
authors.lastname: De Deyn
authors.forename: J M
authors.initials: JM
authors.lastname: Trijbels
authors.forename: F
authors.initials: F
authors.lastname: Hanefeld
mesh_terms: D000284:Administration, Oral; D000592:Amino Acid Metabolism, Inborn Errors / Q000201:enzymology / Q000378:metabolism*; D003401:Creatine / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use*; D003404:Creatinine / Q000378:metabolism; D006146:Guanidines / Q000097:blood* / Q000134:cerebrospinal fluid / Q000652:urine; D050937:Guanidinoacetate N-Methyltransferase; D006801:Humans; D007223:Infant; D008297:Male; D008780:Methyltransferases / Q000172:deficiency*; D009069:Movement Disorders / Q000201:enzymology / Q000235:genetics; D009952:Ornithine / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D006146:Guanidines; D003404:Creatinine; D009952:Ornithine; D008780:Methyltransferases; C494506:GAMT protein, human; D050937:Guanidinoacetate N-Methyltransferase; D003401:Creatine